Accutar Biotechnology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Accutar Biotechnology sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Accutar Biotechnology: 4 sponsored US clinical trials, 1 recruiting.
Accutar Biotechnology sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed/Refractory B-cell Malignancies, with 1 trials.
Upper-quartile sponsor footprint
Accutar Biotechnology sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05241613
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
NCT05080842
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the Accutar Biotechnology pipeline
1 recruiting of 4 indexed (25% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Relapsed/Refractory B-cell Malignancies (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Accutar Biotechnology: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Accutar Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Accutar Biotechnology page
4 registered trials is a research-attention snapshot, not an endorsement of Accutar Biotechnology or any single study.
- 1 of Accutar Biotechnology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed/Refractory B-cell Malignancies is the condition Accutar Biotechnology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed/Refractory B-cell Malignancies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Accutar Biotechnology pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.